Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06346067 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
A Phase 3 study of Advanced or Metastatic NRAS-mutant Melanoma, sponsored by Erasca.
- Active
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT06346067 is a Phase 3 study of Advanced or Metastatic NRAS-mutant Melanoma that is active but no longer recruiting, run by Erasca. The registered enrollment target is 78 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT06346067, a Phase 3 study of Advanced or Metastatic NRAS-mutant Melanoma, is active but no longer recruiting, sponsored by Erasca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Trametinib
- DRUG Dacarbazine
- DRUG Naporafenib
Study Locations (20)
Texas
- Texas Oncology- Austin Midtown - Austin
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Florida
- Mayo Clinic - Florida - Jacksonville
- University of Miami Sylvester Cancer - Miami
Arizona
- Mayo Clinic - Arizona - Phoenix
California
- University of California, San Francisco - San Francisco
Colorado
- The Melanoma and Skin Care Institute - Englewood
Kansas
- University of Kansas Cancer Center - Kansas City
Louisiana
- Ochsner Clinic Foundation - Jefferson
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06346067
The ClinicalTrials.gov registry entry for NCT06346067 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic NRAS-mutant Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT06346067 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Texas, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06346067 about?
NCT06346067 is a clinical study titled "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)". Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of...
What is the current status of trial NCT06346067?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2024-04-29. Estimated completion is 2028-12.
What conditions does trial NCT06346067 study?
This clinical trial studies the following conditions: Advanced or Metastatic NRAS-mutant Melanoma.
What interventions are being tested in trial NCT06346067?
The interventions under investigation include: Temozolomide (DRUG), Trametinib (DRUG), Dacarbazine (DRUG), Naporafenib (DRUG).
Who is sponsoring clinical trial NCT06346067?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06346067 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.